Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.
about
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancerInhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARATransforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-betaTransforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell linesAdvances in cancer vaccine development.Medical applications of transforming growth factor-betaTGF-beta-based immunotherapy for cancer: breaching the tumor firewall.Anti-HER2 vaccines: new prospects for breast cancer therapyRole of TGF-beta in immune-evasion of cancer.Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape.Efficient delivery of DNA and morpholinos into mouse preimplantation embryos by electroporationIsolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization.Immunotherapy of brain cancers: the past, the present, and future directions.All in the head: obstacles for immune rejection of brain tumours.Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.Strategies for reversing drug resistance.Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research.Immunotherapeutic strategies for malignant glioma.Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients.Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma.Immunotherapy for human glioma: innovative approaches and recent results.Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells.The rationale for prophylactic cancer vaccines and need for a paradigm shift.The tumour microenvironment and implications for cancer immunotherapy.The roles for cytokines in the generation and maintenance of regulatory T cells.Nanoparticle delivery systems in cancer vaccines.Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells.A review of vaccine clinical trials for non-small cell lung cancer.Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brainMolecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.Immunotherapeutic approaches for gliomaA novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells.TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.Cancer-associated fibroblasts as targets for immunotherapyTransforming growth factor-beta and its implication in the malignancy of gliomas.A pivotal role for the transmembrane domain in transforming growth factor-beta receptor activation.
P2860
Q24625197-5BEF1DF3-07C6-4A02-9277-DE19A2FFAD23Q24671742-4179393F-3BF2-41E9-BD0C-65C1D2672DC8Q24793319-AF5FC12B-32A2-46DA-B473-9DCE9E7383E3Q28138728-7F7E333C-8835-4683-8C6A-F956F649BD8CQ33603404-B573C283-DB26-4DFA-A474-8A96F872C37AQ33723271-47AD4FF1-18E4-4A17-B4EB-36BCAB6E0B91Q34057799-DFE3567C-24CA-4AC5-B388-FD67E0E44630Q34105959-06A01993-5C51-4672-A317-BEC8BB6EAF48Q34136492-6A0874EB-C71A-4529-8CA3-4FA7A5286898Q34136498-E2B5F66C-4349-4290-8430-6E78B3166689Q34395973-B9BD50FE-D7D1-4D58-9BE9-99B0655B49C6Q34565145-193781E9-49DB-4972-BDB1-3BB3B761BCF0Q34701587-8BFBED00-7828-45FD-92B2-94DFB0FACD85Q34842204-CE723EE1-21BD-40D3-92B0-3799659EF6CCQ35113661-64345531-F3AC-44D0-AF98-CA6B9A9EDF55Q35567287-9EB28791-250F-468F-A7A7-216517FEAAD9Q35682205-53C63951-8DD8-4F64-A0A3-5A8C5076A4CFQ35778576-76B39223-2C9F-4737-9D8E-E4412D174898Q35787792-0DFC6B3F-E424-4BBD-B483-F76723299999Q35847139-FEEAFEBD-8697-4A88-8405-FC7E9A2D27C4Q35890860-D237E0BC-D350-49A2-A98A-1CB314099AD3Q36284489-06BB76F5-2BDE-4312-A37C-9800AF1BB6E3Q36380683-8C701E27-0163-42BF-86F7-51DBB41697D8Q36401309-57A7D62A-2D62-43B3-AF53-47E323EAFF30Q36423899-E34880D8-770A-408A-86AB-D0E4E4F30200Q36521830-10C208AB-85A1-4686-83E8-F4E14B9144F2Q36563513-0FEBA794-F573-499C-83DA-9D74408DD6A9Q36574571-A7A41279-DF59-4006-8D07-2C37931161C8Q36642213-41956BD2-0C11-480C-9F75-6A2B7EE5A569Q36675454-3E91E4E8-E38A-4A34-923C-4A7C53F10EFFQ36756669-F42A7691-F34D-4320-B0EE-7C1B09739760Q37003699-1C768849-9D7C-4E63-960A-620DB2A8A53CQ37078733-F107DB7C-91F6-4762-8DC9-2A629BAF7D87Q37079854-975AF8ED-8634-4FA4-9826-ECCB3E8DE1F5Q37267793-6A92D8BC-A6CC-4790-AA14-6819220B75CBQ37537012-4BD5041A-A9D9-4E6A-A202-214E7279C3FEQ37900199-E306F71A-B391-46D6-BFD3-34DD5C2701E0Q38063582-95C027B9-3293-4E4D-9891-533087367544Q38192972-68CDB81B-42A6-4D52-A453-1065E2225DECQ38325880-72C64F5A-2454-4E86-9FAC-1F27FB3EDB6B
P2860
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Eradication of established int ...... r beta antisense gene therapy.
@en
Eradication of established int ...... r beta antisense gene therapy.
@nl
type
label
Eradication of established int ...... r beta antisense gene therapy.
@en
Eradication of established int ...... r beta antisense gene therapy.
@nl
prefLabel
Eradication of established int ...... r beta antisense gene therapy.
@en
Eradication of established int ...... r beta antisense gene therapy.
@nl
P2093
P2860
P356
P1476
Eradication of established int ...... r beta antisense gene therapy.
@en
P2093
D L Shawler
P2860
P304
P356
10.1073/PNAS.93.7.2909
P407
P577
1996-04-01T00:00:00Z